Susquehanna International Group, LLP Pharma Cyte Biotech, Inc. Transaction History
Susquehanna International Group, LLP
- $560 Billion
- Q3 2024
A detailed history of Susquehanna International Group, LLP transactions in Pharma Cyte Biotech, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 35,228 shares of PMCB stock, worth $59,535. This represents 0.0% of its overall portfolio holdings.
Number of Shares
35,228
Previous 54,834
35.76%
Holding current value
$59,535
Previous $107,000
37.38%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding PMCB
# of Institutions
30Shares Held
932KCall Options Held
0Put Options Held
0-
K2 Principal Fund, L.P. Toronto, A6209KShares$353,6590.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA192KShares$325,1340.0% of portfolio
-
Geode Capital Management, LLC Boston, MA168KShares$284,2580.0% of portfolio
-
Ayrton Capital LLC Westport, CT92.1KShares$155,6277.31% of portfolio
-
Equitec Proprietary Markets, LLC82.7KShares$139,8080.17% of portfolio
About PharmaCyte Biotech, Inc.
- Ticker PMCB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,750,100
- Market Cap $35.1M
- Description
- PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types o...